

Date: 9 August 2022

**Re: Freedom of Information Request**  
**Ref: 247-2022**

Thank you for your email dated the 14<sup>th</sup> July 2022, requesting information in relation to DLBCL treatment.

The information you require is as follows:

**Q1. Does your trust treat patients with Diffuse Large B Cell Lymphoma (DLBCL)? If not, then which trust do you refer DLBCL patients to?**

**YES**

**Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL)?**

**153**

**Q3. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:**

<b>R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)</b>	<b>31</b>
<b>R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)</b>	<b>7</b>
<b>Other immuno-chemotherapy</b>	<b>0</b>
<b>Stem cell transplant or bone marrow transplant (autologous or allogeneic)</b>	<b>&lt;5</b>
<b>Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - any line of treatment</b>	<b>&lt;5</b>
<b>Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - third-line treatment only</b>	<b>0</b>
<b>Tisagenlecleucel</b>	<b>0</b>
<b>Axicabtagene ciloleucel</b>	<b>0</b>
<b>Lisocabtagene maraleucel</b>	<b>0</b>
<b>Other chemotherapy :</b>	

**BEAM** **<5**

Bendamustine + Obinutuzumab	<5
Bendamustine+Polatuzmab vedot+Ritux	<5
Bendamustine+Rituximab(Sub Courses)	<5
CVP + Obinutuzumab	<5
CVP R	<5
CYC ETOP RITU VINC(RCEOP)	<5
Cytarabine + Methotrexate + Rituximab + Thiotepa (MATRIX)	<5
DA EPOCH	<5
DA EPOCH R	<5
DHAP - R	<5
Etoposide oral	<5
Ibrutinib	<5
Immunoglobulin INTRATECT 10%	<5
Lenalidomide	6
Lomustine	27
Methotrexate intrathecal	<5
METHOTREXATE PROCARBAZINE RITUXIMAB	<5
Obinutuzumab Maintenance	<5
Olaparib/Placebo (Paradigm trial)	<5
Procarbazine	12
R CODOX M	<5
R GCVP	<5
R IVAC	<5
R-GDP	<5
Rituximab	13
Temozolamide	48
Temozolomide + RT	23
Triple Intrathecal	<5

**Q4. In the last 6 months, how many Diffuse Large B Cell Lymphoma (DLBCL) patients have you referred to other trusts for:**

Stem cell transplant or bone marrow transplant (autologous or allogeneic)	0
CAR-T therapy (Tisagenlecleucel, Axicabtagene ciloleucel, Lisocabtagene maraleucel)	0

**Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part?**

**The Clatterbridge Cancer Centre does not have trials currently open and active for Diffuse Large B-Cell Lymphoma (DLBCL).**

**There is a trial called PROACT looking at cardio toxicity from cancer treatments where patients with this cancer may take part.**

**Preventing cardiac damage in patients treated for breast cancer: a phase 3 Randomised, Open label, blinded endpoint, trial of enalapril to prevent Anthracycline-induced CardioToxicity (PROACT), currently less than 5 participants on the study.**

**Where a dataset includes a small number of patients, and it has been deemed to pose a risk of patient re-identification when combined with another dataset, the number has been stated as <5.**

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

**In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:**

<https://forms.office.com/r/eLzHXi49Ea>



Kind Regards,

The Information Governance Team  
Contact Email: [ccf-tr.foi@nhs.net](mailto:ccf-tr.foi@nhs.net)